MassDevice.com +3 | The top 3 medtech stories for September 2, 2015

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. FDA approves Wright Medical’s Augment bone-growth putty Wright Medical said that the FDA approved the Augment bone-growth putty it acquired when it closed a $380 million buyout of BioMimetic Therapeutics in 2013. Pre-market approval from the FDA means Wright can begin marketing Augment in the U.S. as an alternative to autograft for ankle and hindfoot fusion procedures, the Memphis-based company said. Read more 2. HeartWare inks $929m deal for Valtech Cardio’s mitral and tricuspid valves HeartWare International said that it agreed to put roughly $929 million on the table for Israeli replacement heart valve maker Valtech Cardio. Terms of the deal call for an up-front payment of 4.4 million shares of HeartWare stock, which would be worth about $360 million at yesterday’s closing price of $81.81. The buyout also includes milestones of 800,000 shares when Valtech’s Cardioband annuloplasty device wins CE Mark approval in the European Union, worth $65.4 million at yesterday’s price, and another 700,000 shares (worth $57.3 million) on the earlier of 1st-in-human implants for either the Cardioband tricuspid or CardioV...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 3 Source Type: news